Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.
KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.
Promising phase III results for RUBY suggest expanded use of Jemperli (dostarlimab-gxly) paired with other treatments in cases of initial severe or returning uterine cancer.
Benzoyl peroxide, a small molecule drug with potent antibacterial properties, was originally sanctioned in January 1968 by Maruho Pharmaceutical for treating acne.
Lirum BioMed Reveals Encouraging Results for Its Innovative Treatment LX-101, Showing Strong Early-Phase Effectiveness in Tackling IGF-Linked Tumors, Scheduled for Discussion at the 2024 ESMO Congress on Sarcoma and Uncommon Cancers.